Skip to main content

Journal Club

Tumor/Skull Base

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Cancer Cell | 2010

Rapid review note

Journal Club is a rapid, AI-assisted appraisal layer. It highlights study design, effect estimates, and practice relevance, but it is still a briefing, not a replacement for the paper.

For education only. Not medical advice.

Paper snapshot

Rapid study overview

Open paper

DOI

10.1016/j.ccr.2009.12.020

PMID

20129251

PICO

Population

Adult patients with glioblastoma multiforme (GBM)

Intervention

Integrated genomic analysis (gene expression, mutations, copy number) to define molecular subtypes

Comparator

No direct comparator; subtypes compared to each other

Outcomes

Subtype classification, genomic aberrations, differential response to aggressive therapy

Design

Type

Observational cohort study using The Cancer Genome Atlas (TCGA) data

Randomized

No

Multicenter

Yes

Blinded

Not applicable: bioinformatics analysis

Follow-up

Not reported in excerpt

Primary endpoint

Identification of four robust GBM subtypes (Proneural, Neural, Classical, Mesenchymal) through consensus clustering

Secondary endpoints

  • Association of subtypes with specific genomic abnormalities
  • Differential response to aggressive therapy by subtype

Practice impact

What this means

This TCGA analysis identifies four molecular GBM subtypes (Proneural, Neural, Classical, Mesenchymal) defined by distinct genomic abnormalities. The Classical subtype showed greatest benefit from aggressive therapy while Proneural showed none. This framework supports biologically-informed stratification but requires prospective validation.

Bottom line

Establishes molecular classification framework for GBM with therapeutic implications

Strength of evidence

moderate

Recommendation

consider change

Why it matters

  • Provides biologically coherent subtypes linked to genomic drivers
  • Suggests differential response to aggressive therapy by subtype

What would change my mind

  • Prospective validation showing subtype-specific treatment benefit
  • Randomized trials using subtype-guided therapy
  • Independent replication in diverse clinical settings

Critical appraisal

How strong is the paper?

Methods critique

Risk of bias

High: retrospective analysis of convenience sample without prospective validation; clustering methods may impose structure

Confounding

High: treatment heterogeneity not controlled; clinical variables not fully integrated in subtype definition

Missing data

Moderate: 173 of 202 samples identified as 'core samples' with positive silhouette width

Multiplicity

High: extensive multiple testing in genomic analyses without clear correction strategy

Notes

  • Consensus clustering used to identify robust clusters
  • SigClust used to evaluate cluster significance

Stats check

NNT

N/A

Effect sizes

  • Consensus clustering identified 4 subtypes from 202 samples
  • 173 core samples identified with positive silhouette width

Absolute effects

  • Greatest benefit from aggressive therapy in Classical subtype
  • No benefit from aggressive therapy in Proneural subtype

Concerns

  • No comparative statistics for therapy response reported in excerpt
  • Clustering stability assessed visually without quantitative thresholds

External validity

Who it applies to

Adult GBM patients similar to TCGA cohort (median survival ~1 year)

Who it does not

Pediatric GBM, low-grade gliomas, non-TCGA treatment populations

Generalizability notes

  • Based on TCGA research network data
  • Requires validation in independent cohorts

Evidence trace

Source trace and metadata

Citations (3)

claim_id

methods_critique.risk_of_bias

locator

p. 2 Results

quote

Consensus average linkage hierarchical clustering of 202 samples and 1,740 genes identified four robust clusters

claim_id

stats_check.effect_sizes

locator

p. 2 Results

quote

Samples most representative of the clusters, hereby called 'core samples' (n=173 of 202)

claim_id

practice_impact.bottom_line

locator

p. 1 Summary

quote

Response to aggressive therapy differs by subtype with greatest benefit in Classical and no benefit in Proneural

Metadata

Generated at

2026-03-06T13:41:29.251Z

Version

top 100 cited in past 20 years